» Articles » PMID: 19945097

Cancers, Infections, and Endocrine Diseases in Women with Endometriosis

Overview
Journal Fertil Steril
Date 2009 Dec 1
PMID 19945097
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the prevalence of patient-reported, physician-diagnosed comorbid conditions in women with endometriosis.

Design: Cross-sectional study of self-reported survey data.

Setting: Academic research.

Patient(s): Four thousand three hundred thirty-one Endometriosis Association (EA) members reporting surgically diagnosed endometriosis.

Intervention(s): None.

Main Outcome Measure(s): Self-reported, physician-diagnosed infectious diseases, cancers, and endocrine diseases.

Result(s): Nearly two-thirds of women reported one or more of the assessed conditions. Recurrent upper respiratory infections and recurrent vaginal infections were common and more likely in women responding to the EA survey. Melanoma was reported by 0.7% (n=29), breast cancer by 0.4% (n=16), and ovarian cancer by 0.2% (n=10). While ovarian cancer and melanoma were significantly more common than in the general population, breast cancer was surprisingly less common. Addison's disease and Cushing's syndrome were rare (0.2% and 0.1%, respectively).

Conclusion(s): Respondents reported a higher prevalence of recurrent upper respiratory or vaginal infections, melanoma, and ovarian cancer than the general population. These findings document other potential associations related to the immune system, which may help focus future research into this disease.

Citing Articles

Correlation between dysbiosis of vaginal microecology and endometriosis: A systematic review and meta-analysis.

Qing X, Xie M, Liu P, Feng O, Leng H, Guo H PLoS One. 2024; 19(7):e0306780.

PMID: 38976704 PMC: 11230536. DOI: 10.1371/journal.pone.0306780.


Breast Cancer in Patients with Previous Endometriosis Showed Low Aggressive Subtype.

Vanni G, Selntigia A, Marsella V, Russo C, Pellicciaro M, Materazzo M Medicina (Kaunas). 2024; 60(4).

PMID: 38674271 PMC: 11051959. DOI: 10.3390/medicina60040625.


Identifying therapeutic candidates for endometriosis through a transcriptomics-based drug repositioning approach.

Oskotsky T, Bhoja A, Bunis D, Le B, Tang A, Kosti I iScience. 2024; 27(4):109388.

PMID: 38510116 PMC: 10952035. DOI: 10.1016/j.isci.2024.109388.


A Novel Classification of Endometriosis Based on Clusters of Comorbidities.

Sarria-Santamera A, Yemenkhan Y, Terzic M, Ortega M, Asunsolo Del Barco A Biomedicines. 2023; 11(9).

PMID: 37760889 PMC: 10525703. DOI: 10.3390/biomedicines11092448.


Impact of Hormone Replacement Therapy on Risk of Ovarian Cancer in Postmenopausal Women with De Novo Endometriosis or a History of Endometriosis.

Lee H, Lee B, Choi H, Kim T, Kim Y, Kim Y Cancers (Basel). 2023; 15(6).

PMID: 36980597 PMC: 10046182. DOI: 10.3390/cancers15061708.


References
1.
Martini M, Ciccarone M, Garganese G, Maggiore C, Evangelista A, Rahimi S . Possible involvement of hMLH1, p16(INK4a) and PTEN in the malignant transformation of endometriosis. Int J Cancer. 2002; 102(4):398-406. DOI: 10.1002/ijc.10715. View

2.
Borgfeldt C, Andolf E . Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand. 2004; 83(4):395-400. DOI: 10.1111/j.0001-6349.2004.00305.x. View

3.
Modugno F, Ness R, Allen G, Schildkraut J, Davis F, Goodman M . Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol. 2004; 191(3):733-40. DOI: 10.1016/j.ajog.2004.03.035. View

4.
Baxter S, Thomas E, Campbell I . GSTM1 null polymorphism and susceptibility to endometriosis and ovarian cancer. Carcinogenesis. 2001; 22(1):63-5. DOI: 10.1093/carcin/22.1.63. View

5.
Baranova H, Bothorishvilli R, Canis M, Albuisson E, Perriot S, Glowaczower E . Glutathione S-transferase M1 gene polymorphism and susceptibility to endometriosis in a French population. Mol Hum Reprod. 1997; 3(9):775-80. DOI: 10.1093/molehr/3.9.775. View